Phenytoin Antibody (Mouse Monoclonal)

From: $350.00

Catalog #: A2010005 – 0.25 mg

Mouse monoclonal antibody to phenytoin (a drug used to treat seizures, heart arrhythmia, and neuropathic pain). Six clones are available: 1E5, 4D8, 8H9, 2C6, 5H7 and 9F3. Antibodies can be used in ELISA formats as a well as western blot and other immuno-detection methods. Bulk pricing and biotinylation services are available. Live Enquiry about this product via Text/SMS: 1-858-900-3210 (8 am – 8 pm PST).

Clone Catalog #
1E5 A2010005-1E5
4D8 A2010005-4D8
8H9 A2010005-8H9
2C6 A2010005-2C6
5H7 A2010005-5H7
9F3 A2010005-9F3
6-Clone Set A2010005-SET
Clear

Description

Mouse Phenytoin Antibody (Monoclonal). 6 different clones are available.

Product Data Sheet
Catalog # A2010005-1E5

A2010005-4D8

A2010005-8H9

A2010005-2C6

A2010005-5H7

A2010005-9F3

A2010005-SET

Size 0.25 mg
Other Names Mab to Phenytoin, antibody to Phenytoin
Host Mouse
Concentration 1.0 mg/mL
Purity >90% (protein A column)
Storage -20°C. Avoid repeated freeze/thaw cycles.
Supplied as Liquid solution
Buffer 1X Phosphate Buffer Saline, pH 7.4 + 0.05% sodium azide.
Keywords Phenytoin, mouse monoclonal antibody

 

References

  • Phenytoin: 80 years young, from epilepsy to breast cancer, a remarkable molecule with multiple modes of action. Keppel Hesselink JM, Kopsky DJ. J Neurol. 2017 Aug;264(8):1617-1621.
  • Fosphenytoin and phenytoin in patients with status epilepticus: improved tolerability versus increased costs. DeToledo JC, Ramsay RE. Drug Saf. 2000 Jun;22(6):459-66.
  • Application of in vivo metabolomics to preclinical/toxicological studies: case study on phenytoin-induced systemic toxicity. Kamp H, Fabian E, Groeters S, Herold M, Krennrich G, Looser R, Mattes W, Mellert W, Prokoudine A, Ruiz-Noppinger P, Strauss V, Walk T, Wiemer J, van Ravenzwaay B. Bioanalysis. 2012 Sep;4(18):2291-301.
  • Unbound phenytoin plasma concentrations in patients comedicated with sodium valproate–the predictive value of plasma albumin concentration. Johnson GJ, Kilpatrick CJ, Bury RW, Fullinfaw RO, Moulds RF. Br J Clin Pharmacol. 1989 Jun;27(6):843-9.
  • Phenytoin prodrug 3-phosphoryloxymethyl phenytoin (ACC-9653): pharmacokinetics in patients following intravenous and intramuscular administration. Boucher BA, Bombassaro AM, Rasmussen SN, Watridge CB, Achari R, Turlapaty P. J Pharm Sci. 1989 Nov;78(11):929-32.
  • Pharmacokinetics of phenytoin following intravenous and intramuscular administration of fosphenytoin and phenytoin sodium in the rabbit. Muchohi SN, Kokwaro GO, Maitho TE, Munenge RW, Watkins WM, Edwards G. Eur J Drug Metab Pharmacokinet. 2002 Apr-Jun;27(2):83-9.
  • Phenytoin pharmacokinetics following oral administration of phenytoin suspension and fosphenytoin solution to rats. Burstein AH, Cox DS, Mistry B, Eddington ND. Epilepsy Res. 1999 Apr;34(2-3):129-33.
  • Phenytoin as an effective treatment for polymorphic ventricular tachycardia due to QT prolongation in a patient with multiple drug intolerances. Yager N, Wang K, Keshwani N, Torosoff M. BMJ Case Rep. 2015 Jun 12;2015:bcr2015209521.

Material Safety Data Sheet